Related Experiment Video
Updated: Feb 21, 2026
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
Insights
The UK now offers live attenuated influenza vaccine (LAIV) intranasally to children aged 2-16 not at clinical risk. This review examines the evidence supporting this important public health strategy for pediatric influenza prevention.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Public Health
Background:
- The UK's seasonal influenza vaccination program historically targeted high-risk individuals.
- In 2012, recommendations expanded to include vaccinating children aged 2-16 years not in clinical risk groups.
- This expansion utilizes a live attenuated influenza vaccine (LAIV) administered intranasally, differing from the adult injectable inactivated vaccine.
Purpose of the Study:
- To review the evidence supporting the use of intranasal live attenuated influenza vaccine (LAIV) in children.
- To evaluate the efficacy and safety of LAIV for pediatric influenza prevention in the UK.
- To inform public health policy regarding childhood influenza vaccination.
Main Methods:
- Literature review of studies on intranasal live attenuated influenza vaccine (LAIV) in children.
- Analysis of clinical trial data and observational studies.
- Assessment of vaccine effectiveness, safety, and immunogenicity.
Main Results:
- Evidence indicates LAIV is effective in preventing seasonal influenza in children.
- Safety profile of LAIV in the target pediatric population is generally favorable.
- Intranasal administration offers a needle-free alternative for pediatric vaccination.
Conclusions:
- The use of intranasal live attenuated influenza vaccine (LAIV) is supported by evidence for children aged 2-16 years not at clinical risk.
- This vaccination strategy contributes to broader influenza control efforts in the UK.
- Continued monitoring and research are essential to optimize pediatric influenza vaccination programs.
Abstract:
For many years, the UK seasonal influenza vaccination programme has been offered to people at higher risk from the complications of influenza infection, including those aged over 65 years and anyone aged over 6 months who is in a clinical risk group.1 In 2012, the Joint Committee on Vaccination and Immunisation (JCVI) recommended extending seasonal influenza vaccination to children aged 2-16 years who are not in a clinical risk group.2 In contrast to the vaccination programme for adults, which uses an injectable inactivated influenza vaccine, children are being offered a live attenuated influenza vaccine (LAIV) that is administered intranasally.2 Here, we consider the evidence for the use of the intranasal influenza vaccine for children who are not in a clinical risk group.
